Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI with Vasovist vs Magnevist in untreated squamous cell cervical carcinoma
2008-002958-37Phase 3Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jul 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of gadofosveset and gadopentetate dimeglumine in cervical squamous cell carcinoma (CSCC) and Cervical Cancer (CC) (2 arms), sponsored by European Institute of Oncology. Primary endpoint: Ktrans differences. Started Jul 2008; status: terminated.
02
Drugs
gadofosvesetgadopentetate dimeglumine
03
Conditions
cervical squamous cell carcinoma (CSCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2008-002958-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002958-37.